Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

PHASE2TerminatedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

November 30, 2009

Conditions
Methamphetamine Dependence
Interventions
DRUG

CPP-109 vigabatrin

tablets, bid for 12 weeks

DRUG

Matching Placebo

tablets, bid, 12 weeks

Trial Locations (8)

Unknown

North County Clinical Research (NCCR), Oceanside

South Bay Treatment Center, San Diego

Addiction Pharmacology Research Laboratory, St. Luke's Hospital, San Francisco

START Research and Treatment, Kansas City

Creighton University Medical Center, Omaha

Behavioral Health Research Center of the Southwest, Albuquerque

Pahl Pharmaceutical Research, Oklahoma City

Pillar Research, Dallas

Sponsors
All Listed Sponsors
lead

Catalyst Pharmaceuticals, Inc.

INDUSTRY

NCT00730522 - Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence | Biotech Hunter | Biotech Hunter